BioAlliance Announces Positive Preliminary Pivotal Phase III Results in Herpes Labialis with Acyclovir Lauriad®

News   Aug 27, 2009

 
BioAlliance Announces Positive Preliminary Pivotal Phase III Results in Herpes Labialis with Acyclovir Lauriad®
 
 
 

RELATED ARTICLES

Apple Allergens as an Effective Option for Treating Apple Allergy

News

Researchers have now proven in a Phase II trial that the apple allergen "Mal d 1" significantly reduces the symptoms of apple allergy and is therefore an effective and safe treatment option.

READ MORE

Blockchain & AI for Biomedical Applications

News

Biogerontology Research Foundation Chief Science Officer (CSO) co-authored the landmark paper in the journal Oncotarget on the convergence of blockchain and AI to decentralize and galvanize healthcare and biomedical research.

READ MORE

Vaccine Against Diabetes Closer Than Ever

News

Scientists at the University of Tampere (Finland) and the Karolinska Institutet (Sweden) have demonstrated that an enterovirus vaccine can protect against virus-induced diabetes in a mouse model for Type 1 diabetes.

READ MORE

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE